Log in to search using one of your social media accounts:

 

European Commission grants orphan drug status to Apogenix ’s asunercept for MDS
German biopharmaceutical company Apogenix ’s asunercept (APG101) has received orphan drug designation from the European Commission (EC) to treat patients with myelodysplastic syndromes (MDS). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 8, 2017 Category: Pharmaceuticals Source Type: news

Luspatercept Eyes Treatment of Anemia in Low-Risk MDS Luspatercept Eyes Treatment of Anemia in Low-Risk MDS
Luspatercept, an investigational agent, shows promise in treating anemia in low-risk myelodysplastic syndromes based on a phase 2 study. Larger studies are underway.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: MDS symptoms: What are the signs of pre-leukemia?
MDS, or myelodysplastic syndrome, refers to a group of blood cancers. In this article, learn about the symptoms and complications of this disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 15, 2017 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Gamida Cell launches severe aplastic anemia trial
Gamida Cell said today that the first patient has been transplanted in a study of its CordIn product for patients with severe aplastic anemia or hypoplastic myelodysplastic syndrome. The product is designed for patients with rare genetic diseases who have no fully-matched donors for a bone marrow transplantation. Gamida Cell said it is also evaluating its CordIn therapy for patients with sickle cell disease. Get the full story at our sister site, Drug Delivery Business News.   The post Gamida Cell launches severe aplastic anemia trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Research & Development Stem Cells Gamida Cell Source Type: news

Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS
This investigator initiated study is being conducted in collaboration with the U.S. National Heart, Lung and Blood Institute (NHLBI) JERUSALEM, Aug. 21, 2017 -- (Healthcare Sales & Marketing Network) -- The first subject has been transplanted in an in... Biopharmaceuticals Gamida Cell, Cordin, aplastic anemia, myelodysplastic syndrome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 21, 2017 Category: Pharmaceuticals Source Type: news

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
This research article has led to a Practice Changing Update on DynaMed Plus. It found that myeloablative conditioning increases relapse-free survival, but also increases treatment-related mortality compared to reduced intensity conditioning in patients with acute myeloid leukemia or myelodysplastic syndromes having first allogeneic hematopoietic cell transplantation (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 30, 2017 Category: Consumer Health News Source Type: news

FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas
The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 29, 2017 Category: American Health Source Type: news

Helsinn and MEI begin dosing in Phase II combination trial to treat MDS
Swiss pharmaceutical group Helsinn and US-based oncology firm MEI Pharma have begun dosing patients in a Phase II clinical trial of pracinostat and azacitidine combination for the treatment of patients with myelodysplastic syndromes (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - June 15, 2017 Category: Pharmaceuticals Source Type: news

Survival in MDS Equivalent With Reduced-Intensity Conditioning
Patients with myelodysplastic syndrome undergoing a reduced –intensity conditioning regimen prior to allogeneic stem-cell transplantation had similar 2-year survival outcomes as patients who underwent myeloablative conditioning. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Myelodysplastic Syndromes News Source Type: news

Results of prospective randomized phase III study of the EBMT (Ricmac trial) dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation for patients with myelodysplastic syndrome
(European Society for Blood and Marrow Transplantation) The EBMT announces the results from the RICMAC trial, published in the Journal of Clinical Oncology on Tuesday 2 May 2017. These results show evidence that reduced-intensity conditioning regimen (RIC) result in at least a 2-year relapse-free survival and overall survival similar to standard conditioning regimen (MAC) in patients with MDS or secondary acute AML. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 4, 2017 Category: Global & Universal Source Type: news

Researchers reveal developmental mechanisms behind rare bone marrow disorder
(Charit é - Universit ä tsmedizin Berlin) Myelodysplastic syndrome is an umbrella term used to describe disorders characterized by the bone marrow's inability to produce normal blood cells. Researchers from Charit é - Universit ä tsmedizin Berlin have found that a mutation in a specific tumor suppressor gene is one possible reason why children with a very rare genetic disorder develop myelodysplastic syndrome. Results from this research have been published in the current edition of the Journal of Clinical Investigation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 12, 2017 Category: Global & Universal Source Type: news

FibroGen to initiate Phase II/III trial of roxadustat to treat MDS related anaemia in China
US-based biopharmaceutical firm FibroGen has secured approval from the China Food and Drug Administration (CFDA) to initiate a Phase II/III clinical trial of roxadustat to treat anaemia associated with lower risk myelodysplastic syndromes (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - April 3, 2017 Category: Pharmaceuticals Source Type: news

UAMS Gets $1.7M NIH Grant to Study Therapy Against Blood Cancer
The University of Arkansas for Medical Sciences has received a $1.7 million grant from the National Institutes of Health to study a potential new therapy to reduce the risk of blood cancer caused by ionizing radiation. Dr. Daohong Zhou received the grant for his team's work addressing whether the ability to restore the fitness of a person’s blood cell-generating cells after radiation can prevent blood cancers like leukemia or bone marrow disorders. UAMS said that out of all cases of myelodysplastic syndrome and leukemia, up to 20 percent are considered to be caused by ionizing radiation exposure and chemotherapy.&nbs...
Source: Arkansas Business - Health Care - March 30, 2017 Category: American Health Source Type: news

Researchers show p300 protein may suppress leukemia in MDS patients
(University of Miami Miller School of Medicine) Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that p300, a protein that increases gene expression by attaching acetyl molecules to DNA, may stop myelodysplastic syndrome (MDS) from developing into acute myeloid leukemia (AML). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 27, 2017 Category: Cancer & Oncology Source Type: news

EPREX ® (epoetin alfa) Marketing Authorisation Extended to Include Treatment of Symptomatic Anaemia in Patients with Low or Intermediate-1-Risk Myelodysplastic Syndromes
French Health Authority ANSM grants approval in the Mutual Recognition Procedure; the relevant health authorities are required to implement the new indication within 30 days (Source: Johnson and Johnson)
Source: Johnson and Johnson - March 24, 2017 Category: Pharmaceuticals Source Type: news

Navigating Treatment Options in Low-Risk Myelodysplastic Syndromes
This video explores the current treatment landscape for lower-risk MDS patients, including the various agents and sequencing strategies employed to best optimize outcomes. (Source: CancerNetwork)
Source: CancerNetwork - March 16, 2017 Category: Cancer & Oncology Authors: Valeria Santini, MD Tags: Myelodysplastic Syndromes Videos Hematologic Malignancies Source Type: news

FDA grants orphan drug designation to Boehringer Ingelheim ’s antibody BI 836858
The US Food and Drug Administration (FDA) has granted orphan drug designation to Boehringer Ingelheim ’s anti-CD33 monoclonal antibody, BI 836858, which is being investigated in the treatment of myelodysplastic syndromes (MDS). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 13, 2017 Category: Pharmaceuticals Source Type: news

PodMed: A Medical News Roundup From Johns Hopkins (with audio)
(MedPage Today) -- This week's topics include sickle cell trait and HbA1c, carcinogen levels and e-cigarettes, mutations and myelodysplastic syndrome, and kids ingesting pet medicines (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 11, 2017 Category: American Health Source Type: news

Eltrombopag Improved Platelet Counts in Thrombocytopenic MDS Patients
The use of the thrombopoietin receptor agonist eltrombopag was clinically effective at raising platelet counts in patients with lower-risk myelodysplastic syndromes with severe thrombocytopenia. (Source: CancerNetwork)
Source: CancerNetwork - February 10, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Myelodysplastic Syndromes News Source Type: news

Genetic profiling can guide stem cell transplantation for patients with myelodysplastic syndrome
(Dana-Farber Cancer Institute) A single blood test and basic information about a patient's medical status can indicate which patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant, according to new research by scientists at Dana-Farber Cancer Institute. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 8, 2017 Category: Cancer & Oncology Source Type: news

Mayo Clinic: Association between autoimmune disease and bone marrow disorders
(Mayo Clinic) Mayo Clinic researchers have found that azathioprine, a drug commonly used to treat autoimmune disease, may increase the risk of myeloid neoplasms. Myeloid neoplasms include a spectrum of potentially life-threatening bone marrow disorders, such as myelodysplastic syndromes and acute myeloid leukemia. The results are published in JAMA Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 2, 2017 Category: Global & Universal Source Type: news

Mayo Clinic researchers find association between therapy for autoimmune disease and bone marrow disorders
PHOENIX ? Mayo Clinic researchers have found that azathioprine, a drug commonly used to treat autoimmune disease, may increase the risk of myeloid neoplasms. Myeloid neoplasms include a spectrum of potentially life-threatening bone marrow disorders, such as myelodysplastic syndromes and acute myeloid leukemia. The results are published in JAMA Oncology. Researchers analyzed more than 40,000 [...] (Source: Mayo Clinic Arizona News)
Source: Mayo Clinic Arizona News - February 1, 2017 Category: Hospital Management Source Type: news

Devon boy is only child in Britain with a debilitating disease which is baffling doctors
Brave Oliver Brown has rare bone marrow disorder Myelodysplastic Syndrome. The youngster, from Plymouth in Devon, will have a transplant while doctors race to learn more about the disease. (Source: the Mail online | Health)
Source: the Mail online | Health - January 14, 2017 Category: Consumer Health News Source Type: news

Outlook for 2017: Acute Leukemias, MDS, and CLL
This look ahead at hematologic malignancies in 2017 focuses on new agents being studied for the treatment of acute leukemias, myelodysplastic syndromes, and chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 26, 2016 Category: Cancer & Oncology Authors: Guido Marcucci, MD Tanya Siddiqi, MD Tags: Conferences/Hematologic Malignancies Year in Review 2016 Source Type: news

Chinese herbal treatment shows signs of effectiveness in bone marrow recovery
FINDINGSUCLA researchers have found that a Chinese herbal regimen called TSY-1 (Tianshengyuan-1) increased telomerase activity in normal blood cells but decreased it in cancer cells. Telomerase is an enzyme responsible for the production of telomeres, which play an important role in the regulation of normal cell division. These results indicate that telomerase-based treatments may play an important role in treating both blood cell deficiency and cancer.BACKGROUNDMore than 80 percent of cancers have increased telomerase activity, and other medical conditions are also associated with decreased or abnormal telomerase function...
Source: UCLA Newsroom: Health Sciences - December 14, 2016 Category: Universities & Medical Training Source Type: news

Treatment Approaches for Therapy-Related AML, MDS Based on Mutation Profiles
This video examines different mutational profiles of therapy-related myeloid neoplasms and how they can affect approaches to treatment. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2016 Category: Cancer & Oncology Authors: Michael Heuser, MD Tags: Conferences/ASH 2016 Street Team Myelodysplastic Syndromes Source Type: news

Moffitt Cancer Center study shows improved response rates in myelodysplastic syndromes patients treated with lenalidomide and epoetin alpha
(H. Lee Moffitt Cancer Center& Research Institute) Patients with myelodysplastic syndromes (MDS) suffer from a reduction in the number of different types of blood cells, including red blood cells leading to the development of anemia. Many patients with lower-risk MDS benefit from treatment with recombinant-erythropoietin (rHuEPO), which stimulates blood cell production. However, patients who become refractory to rHuEPO have few effective treatment options. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2016 Category: Cancer & Oncology Source Type: news

Imago BioSciences begins enrolment for Phase I/II study of IMG-7289 to treat AML and MDS
US-based pharmaceutical company Imago BioSciences has begun enrolment for its Phase I/II study of IMG-7289 to treat high-risk acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - November 10, 2016 Category: Pharmaceuticals Source Type: news

PR1 Peptide Vaccine May Aid Leukemia Remission PR1 Peptide Vaccine May Aid Leukemia Remission
PR1 peptide vaccine may benefit many patients with myeloid leukemia, chronic myeloid leukemia and myelodysplastic syndrome, findings from an early clinical trial suggest.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 9, 2016 Category: Allergy & Immunology Tags: Public Health & Prevention News Source Type: news

Syros begins Phase II clinical trial of SY-1425 to treat AML and MDS
US-based Syros Pharmaceuticals has initiated its Phase II clinical trial of SY-1425 by dosing the first patient suffering from relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - September 25, 2016 Category: Pharmaceuticals Source Type: news

MDS Risk Scores Need More Honing (CME/CE)
(MedPage Today) -- All myelodysplastic syndromes scoring systems'accuracy dipped over time (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - September 1, 2016 Category: Primary Care Source Type: news

Study shows cell-free DNA sequencing is more accurate for diagnosing myelodysplastic syndrome
(Mary Ann Liebert, Inc./Genetic Engineering News) Using next-generation sequencing methods to analyze cell-free DNA in the blood of patients with myelodysplastic syndrome yields more accurate results than the current standard approach of Sanger sequencing. This finding, and the greater likelihood of detecting the genetic abnormality responsible for the disorder by analyzing cell-free DNA versus DNA extracted from a patient's blood cells, is reported in a new study published in Genetic Testing and Molecular Biomarkers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 2, 2016 Category: Global & Universal Source Type: news

Lenalidomide Helps Some With Myelodysplastic SyndromesLenalidomide Helps Some With Myelodysplastic Syndromes
In certain patients with lower risk myelodysplastic syndromes, lenalidomide (Revlimid, Celgene) can improve quality of life and reduce the need for red blood cell (RBC) transfusions, according to findings from international investigators. Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 6, 2016 Category: Pathology Tags: Pathology & Lab Medicine News Source Type: news

Kura Oncology begins dosing in Phase II trial of tipifarnib to treat lower risk MDS
US-based biopharmaceutical company Kura Oncology has dosed its first patient in a Phase II clinical trial of farnesyl transferase inhibitor, tipifarnib, to treat lower risk myelodysplastic syndromes (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - June 19, 2016 Category: Pharmaceuticals Source Type: news

Largest ever US study launches to research causes and genetics of blood diseases
(ECOG-ACRIN Cancer Research Group) The National Myelodysplastic Syndromes Natural History Study is underway to collect detailed information and biological samples from 2000 adults with myelodysplastic syndromes and 500 patients receiving care for persistent unexplained anemia. A cohort of 1000 patients without disease will serve as a baseline group. With 3500 patients, this is the largest-ever prospective study of MDS in the U.S. Its purpose is to build a national resource to be used by scientists in future research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 25, 2016 Category: Cancer & Oncology Source Type: news

Amgen Highlights Data To Be Presented At 21st Congress Of The European Hematology Association
BLINCYTO® (Blinatumomab) TOWER Study Demonstrates Improved Overall Survival Versus Standard of Care in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia TOWER Study to be Presented at Presidential Symposium as a Best Abstract Sub-group Analyses From Pivotal Head-To-Head Phase 3 Studies Provide Further Insight Into Kyprolis® (Carfilzomib) as Treatment Option for Patients With Multiple Myeloma Aranesp® (Darbepoetin Alfa) Phase 3 ARCADE Data Demonstrates Significant Reduction in Red Blood Cell Transfusions in Anemic Patients With Myelodysplastic Syndrome THOUSAND OAKS, Calif., May 19, 2016 /PR...
Source: Amgen News Release - May 19, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Designing to Deliver Value
With increasing leadership appetite for service models and a plethora of exciting new digital tech, it is easy to get carried away when blueprinting ideas for supportive services. But macro factors, such as shortages in the pool of available digital talent, and the increase of digital noise to cut through, mean it is more important than ever to take a step back and ask if your new service is the best way to actually add value. We’ve distilled three lessons from this year’s ‘Most Valuable HCP or Healthcare Initiative’ nominees to help: 1. Investing in a rigorous needs assessment will pay dividen...
Source: EyeForPharma - April 29, 2016 Category: Pharmaceuticals Authors: Thomas Disley Source Type: news

New Test Diagnoses Cancer Faster, Offers Patients Better Treatment
BOSTON (CBS) – Dr. Mallika Marshall moderated a panel at the 2016 World Medical Innovation Forum Wednesday and learned of a new test that is being used to diagnose and help direct care for patients with certain cancers. “You gotta be kidding me,” was David Gill’s first thought when his doctors told him he had cancer last year. “I had no symptoms. No nothing,” Gill said. The 59-year old Army veteran from Greenland, New Hampshire was diagnosed with myelodysplastic syndrome MDS, a blood cancer which quickly started to transform into acute leukemia. David Gill (WBZ-TV) “Acute leukemia ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 27, 2016 Category: Consumer Health News Authors: deanreddington Tags: Health Local News Seen On WBZ-TV Syndicated Local Watch Listen Dr. Mallika Marshall Rapid Heme Test Source Type: news

What Are Common Causes of Congenital Aplastic Anemia?
Discussion Aplastic anemia are disorders where there is inadequate production of erythrocytes, granulocytes and platelets caused by decreased bone marrow production leading to a peripheral blood pancytopenia. Most often it is acquired because of exposures to infections (especially viruses such as Epstein-Barr virus, rubella, herpes, etc.), drugs (e.g. chloramphenicol, chemotherapeutic agents, etc.), toxins or radiation. Learning Point The most common congenital bone marrow failure syndromes causing pancytopenia are (in this order) Fanconi anemia, Diamond-Blackfan anemia, and Shwachman-Diamond anemia. Most have a variety of...
Source: PediatricEducation.org - April 17, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

For college athlete-turned transplant patient, life’s still a ball
The first time a stem cell transplant recipient leaves his or her quarantined hospital room marks a significant milestone. In the case of Dana Mendes, this move toward independence included an additional step: chasing a ball through the hallways with a stick. For Mendes, 18, it was a return to what she loves. She had been just two days away from her first preseason field hockey practice at Assumption College in August 2015 when a mysterious bout of fatigue was diagnosed as myelodysplastic syndrome (MDS). This precancerous condition, in which immature blood cells in the bone marrow do not mature to become healthy blood cell...
Source: Thrive, Children's Hospital Boston - April 5, 2016 Category: Pediatrics Authors: Saul Wisnia Tags: Diseases & Conditions Our Patients’ Stories Dana-Farber/Boston Children's Cancer and Blood Disorders Center myelodysplastic syndrome stem cell transplant Source Type: news

Seattle Genetics begins trial of vadastuximab talirine combination therapy in MDS patients
US-based Seattle Genetics has started a Phase I/II clinical trial of vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza), a hypomethylating agent (HMA), in patients with previously untreated myelodysplastic syndrome (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - February 23, 2016 Category: Pharmaceuticals Source Type: news

Azacitidine-Induced Cryptogenic Organizing PneumoniaAzacitidine-Induced Cryptogenic Organizing Pneumonia
This case report highlights an important, potentially treatable and rare side effect of azacitidine, a hypomethylating agent used in the treatment of myelodysplastic syndrome. Journal of Medical Case Reports (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 18, 2016 Category: Intensive Care Tags: Hematology-Oncology Journal Article Source Type: news

Phase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS)
First Phase 3 Data From Placebo-Controlled Study With an Erythropoiesis-Stimulating Agent (ESA) in Anemic Patients With MDS Study Met Primary Endpoint and Key Secondary Endpoint of Erythroid Response THOUSAND OAKS, Calif., Feb. 15, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the randomized, double-blind, placebo-controlled Phase 3 Aranesp® (darbepoetin alfa) ARCADE trial met its primary endpoint of reducing the incidence of red blood cell transfusions in anemic patients with low and intermediate-1 risk MDS at the end of the blinded 25-week study period. Aranesp also significantly improved ...
Source: Amgen News Release - February 15, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Summary Information for: PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD)
Labeling, Approval Order, and Summary of Safety and Effectiveness for PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) (H140005). (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - January 14, 2016 Category: Medical Equipment Source Type: news

McMaster researchers reveal predictive staircase to leukemia
(McMaster University) In the paper published today by the scientific journal Cancer Cell, the researchers detail how they have been able to fingerprint myelodysplastic syndromes, a state for blood cells that turns into acute myeloid leukemia cancer in approximately 30 percent of patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 11, 2016 Category: Cancer & Oncology Source Type: news

Study shows age doesn't affect survival outcomes in patients with MDS who receive a HCT
(Padilla Speer Beardsley) Prospective study, presented at the 57th Annual Meeting of the American Society of Hematology, shows age doesn't affect survival outcomes in patients with myelodysplastic syndrome (MDS) who receive a hematopoietic cell transplant. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 6, 2015 Category: Global & Universal Source Type: news

Temple & Fox Chase Cancer Center testing drug for cancer & bone marrow disorders
(Temple University Health System) Temple University Hospital and Fox Chase Cancer Center are the only two sites in Philadelphia that participated in an international phase I, randomized clinical trial which tested the drug guadecitabine (SGI-110) in Myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML). MDS are a group of bone marrow disorders in which the bone marrow doesn't produce enough healthy blood cells. AML is a cancer of the blood and bone marrow. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 18, 2015 Category: Cancer & Oncology Source Type: news

Rich Pharmaceuticals, Inc. Appoints Richard Salvador, Ph.D., Research and Development Expert, To Board of Directors
BEVERLY HILLS, Calif., Aug. 11, 2015 -- (Healthcare Sales & Marketing Network) -- Rich Pharmaceuticals, Inc. (RCHAE) ("Rich Pharmaceuticals" or the "Company") announced today that Dr. Richard A. Salvador will be joining the corporate b... Biopharmaceuticals, Oncology, PersonnelRich Pharmaceuticals, Acute Myelocytic Leukemia, Myelodysplastic Syndromes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 11, 2015 Category: Pharmaceuticals Source Type: news